Vilobelimab is a highly specific first-in-class anti-human C5a monoclonal antibody discovered and developed by InflaRx. Vilobelimab selectively binds to a conformational epitope that is formed upon the cleavage of C5a from C5 and fully blocks C5a while preserving a critical innate defense mechanism, the formation of the membrane attack complex (MAC) and without compromising important upstream functions of the complement system. As of today, there are no approved drugs that specifically target C5a. Vilobelimab is currently being developed in several inflammatory diseases with high unmet medical need.
Vilobelimab is currently in clinical development for several indications.
In preclinical studies, proof of concept was demonstrated for the anti-inflammatory and tissue saving potential of vilobelimab. Vilobelimab has been proven safe and well tolerated in a double-blind placebo-controlled dose escalation Phase I study in healthy human volunteers. In a first clinical Phase IIa multi-center placebo-controlled dose escalation study in patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability as well as selectivity (leaving MAC formation intact).
Vilobelimab holds large potential for treating various inflammatory disease and certain cancers and is in clinical testing for several indications, including Pyoderma Gangraenosum and cSCC.
To learn more about our ongoing phase 3 trial for treating ulcerative pyoderma gangrenosum, please visit clinicaltrials.gov